BlackRock’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,546,289
| Closed | -$4.71M | – | 5690 |
|
|
2023
Q1 | $4.71M | Sell |
2,546,289
-25,167
| -1% | -$31.2K | ﹤0.01% | 3656 |
|
|
2022
Q4 | $2.85M | Sell |
2,571,456
-217,859
| -8% | -$310K | ﹤0.01% | 3976 |
|
|
2022
Q3 | $6.53M | Buy |
2,789,315
+124,992
| +5% | +$443K | ﹤0.01% | 3634 |
|
|
2022
Q2 | $8.07M | Buy |
2,664,323
+197,465
| +8% | +$960K | ﹤0.01% | 3606 |
|
|
2022
Q1 | $16.8M | Sell |
2,466,858
-44,178
| -2% | -$315K | ﹤0.01% | 3286 |
|
|
2021
Q4 | $21M | Sell |
2,511,036
-23,815
| -0.9% | -$196K | ﹤0.01% | 3245 |
|
|
2021
Q3 | $18.8M | Buy |
2,534,851
+77,752
| +3% | +$482K | ﹤0.01% | 3313 |
|
|
2021
Q2 | $16.7M | Buy |
2,457,099
+617,800
| +34% | +$5.13M | ﹤0.01% | 3410 |
|
|
2021
Q1 | $18.9M | Buy |
1,839,299
+292,744
| +19% | +$3.21M | ﹤0.01% | 3216 |
|
|
2020
Q4 | $10.8M | Buy |
1,546,555
+336,420
| +28% | +$2.62M | ﹤0.01% | 3316 |
|
|
2020
Q3 | $9.88M | Sell |
1,210,135
-61,519
| -5% | -$381K | ﹤0.01% | 3225 |
|
|
2020
Q2 | $8.77M | Buy |
1,271,654
+28,788
| +2% | +$155K | ﹤0.01% | 3259 |
|
|
2020
Q1 | $5.9M | Buy |
1,242,866
+4,789
| +0.4% | +$27.6K | ﹤0.01% | 3278 |
|
|
2019
Q4 | $10.8M | Sell |
1,238,077
-25,754
| -2% | -$139K | ﹤0.01% | 3211 |
|
|
2019
Q3 | $4.21M | Buy |
1,263,831
+100,081
| +9% | +$401K | ﹤0.01% | 3534 |
|
|
2019
Q2 | $5.76M | Buy |
1,163,750
+20,646
| +2% | +$110K | ﹤0.01% | 3492 |
|
|
2019
Q1 | $7.09M | Buy |
1,143,104
+77,765
| +7% | +$376K | ﹤0.01% | 3269 |
|
|
2018
Q4 | $3.59M | Sell |
1,065,339
-385,341
| -27% | -$1.8M | ﹤0.01% | 3493 |
|
|
2018
Q3 | $9.43M | Buy |
1,450,680
+55,775
| +4% | +$415K | ﹤0.01% | 3258 |
|
|
2018
Q2 | $10.7M | Buy |
1,394,905
+253,120
| +22% | +$3.65M | ﹤0.01% | 3205 |
|
|
2018
Q1 | $25.5M | Sell |
1,141,785
-20,055
| -2% | -$445K | ﹤0.01% | 2630 |
|
|
2017
Q4 | $14.8M | Buy |
1,161,840
+436,114
| +60% | +$6.41M | ﹤0.01% | 2934 |
|
|
2017
Q3 | $11.3M | Buy |
725,726
+365,497
| +101% | +$5.17M | ﹤0.01% | 3097 |
|
|
2017
Q2 | $5.05M | Buy |
360,229
+97,139
| +37% | +$2.08M | ﹤0.01% | 3467 |
|
|
2017
Q1 | $5.79M | Buy |
+263,090
| New | +$5.57M | ﹤0.01% | 3343 |
|
Other funds holding JNCE
BlackRock's JNCE Position: Q2 2023 in Review
BlackRock sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 2,546,289 shares — an estimated $4.71M sold.
BlackRock first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $25.5M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- BlackRock reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 2,546,289 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.71M.
- BlackRock first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- BlackRock's Jounce Therapeutics, Inc. Common Stock position peaked at $25.5M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.